期刊
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
卷 25, 期 4, 页码 427-435出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.beha.2012.10.005
关键词
acute myelogenous leukemia; AML; histone deacetylase inhibitors; HDAC; treatment; vorinostat
类别
资金
- Merck Co
There is a need for improvements on the results of current therapies for patients with acute myelogenous leukemia (AML). A number of strategies are being used to achieve this goal. Here we present data that indicate that the addition of a histone deacetylase (HDAC) inhibitor, such as vorinostat, to idarubicin and cytarabine results in a very high response rate and can be safely administered to patients with leukemia. These results form the bases of the next SWOG front-line trial in AML Here, we present the rationale for such combination and the studies that led to the support of this concept including both in vitro models and initial phase 1 trials. (C) 2012 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据